Fosun Pharmaceutical

BioNTech and Fosun Pharma form COVID-19 vaccine strategic alliance in China

Retrieved on:

Monday, March 16, 2020

Companies of China, Companies, Fosun International, Economy of China, H shares, Fosun Pharmaceutical, Pharmaceutical industry, Guo Guangchang

If approved, Fosun Pharma will commercialize the vaccine in China.

Key Points:

If approved, Fosun Pharma will commercialize the vaccine in China.
BioNTech will supply the mRNA vaccine for clinical trials from GMP manufacturing facilities in Europe along with its partner Polymun .
Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd (Fosun Pharma, Stock Symbol: 600196.SH, 02196.HK) is a leading healthcare group founded in China.
These forward-looking statements may include, but may not be limited to, the ability of BioNTech and Fosun Pharma to develop and commercialize a vaccine for COVID-19; the potential for a broader collaboration between BioNTech and Fosun Pharma; and the ability to consummate an equity investment by Fosun Pharma in BioNTech.

Ardelyx to Host Conference Call on December 3 to Review Results from the Pivotal Phase 3 PHREEDOM Study

Retrieved on:

Monday, December 2, 2019

Companies, Kyowa Hakko Kirin, Kirin, Clinical medicine, Fosun Pharmaceutical, Irritable bowel syndrome

To participate in the conference call, please dial (855) 296-9612 (domestic) or (920) 663-6277 (international) and refer to conference ID 8065608.

Key Points:

To participate in the conference call, please dial (855) 296-9612 (domestic) or (920) 663-6277 (international) and refer to conference ID 8065608.
Ardelyx is focused on enhancing the way people with cardiorenal diseases are treated by developing first-in-class medicines.
To efficiently bring its treatments to market, Ardelyx is pursuing strategic collaborations for tenapanor for IBS-C and hyperphosphatemia in certain territories.
Ardelyx has established agreements with Kyowa Kirin (formerly known as Kyowa Hakko Kirin) in Japan, Fosun Pharma in China and Knight Therapeutics in Canada.

Ardelyx and Kyowa Kirin Expand Partnership with Two Additional Agreements

Retrieved on:

Monday, November 25, 2019

Companies, Kyowa Hakko Kirin, Kirin, Fosun Pharmaceutical, Fosun International, Monoclonal antibodies, Kirin Company, Kirin Holdings

In return, Kyowa Kirin will pay Ardelyx $10 million ($5 million a year for two years) to support the ongoing research.

Key Points:

In return, Kyowa Kirin will pay Ardelyx $10 million ($5 million a year for two years) to support the ongoing research.
Under the second agreement, Kyowa Kirin has made a $20 million equity investment in Ardelyx at $6.96 for 2,873,563 shares.
Ardelyx and Kyowa Kirin initially established a collaboration partnership in November 2017 througha license agreement that provided Kyowa Kirin with exclusive rights to develop and commercialize Ardelyx's lead investigational product, tenapanor, for the treatment of cardiorenal diseases, including hyperphosphatemia, in Japan.
Ardelyx has established agreements with Kyowa Kirin (formerly known as Kyowa Hakko Kirin) in Japan, Fosun Pharma in China and Knight Therapeutics in Canada.

MimiVax LLC and Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. announce exclusive licensing agreement on SurVaxM for glioblastoma treatment in China

Retrieved on:

Monday, November 18, 2019

Companies of China, Companies, Fosun International, Economy of China, H shares, Fosun Pharmaceutical, Sun Pharmaceutical, Fan Wei

BUFFALO, N.Y. and SHANGHAI, Nov. 18, 2019 /PRNewswire/ -- MimiVax LLC and Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (Fosun Pharma Industrial) today announced the companies have entered into a China-exclusive licensing agreement for SurVaxM, a novel anti-cancer immunotherapy in the treatment of glioblastoma brain cancers.

Key Points:

BUFFALO, N.Y. and SHANGHAI, Nov. 18, 2019 /PRNewswire/ -- MimiVax LLC and Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (Fosun Pharma Industrial) today announced the companies have entered into a China-exclusive licensing agreement for SurVaxM, a novel anti-cancer immunotherapy in the treatment of glioblastoma brain cancers.
Fosun Pharma Industrial is a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co. Ltd (Fosun Pharma), a leading healthcare group in China with extensive healthcare business interests worldwide.
Fosun Pharma will work with MimiVax on the clinical, regulatory and commercial pathways necessary to bring SurVaxM to China.
Established in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196.SH, 02196.HK) is a leading healthcare group in the PRC.

Ardelyx to Host Analyst Day in New York

Retrieved on:

Thursday, October 10, 2019

RTT, Clinical medicine, Medicine, Medical specialties, Abdominal pain, Irritable bowel syndrome, Constipation, Fosun Pharmaceutical

FREMONT, Calif., Oct. 10, 2019 /PRNewswire/ --Ardelyx, Inc. (Nasdaq: ARDX), today announced that it will hold an Analyst Day on Thursday, Oct. 17, 2019, from 7:30 a.m. to 11:00 a.m.

Key Points:

FREMONT, Calif., Oct. 10, 2019 /PRNewswire/ --Ardelyx, Inc. (Nasdaq: ARDX), today announced that it will hold an Analyst Day on Thursday, Oct. 17, 2019, from 7:30 a.m. to 11:00 a.m.
Ardelyx is focused on enhancing the lives of people with cardiorenal diseases by developing first-in-class medicines that matter.
On September 12, 2019, Ardelyx received approval of IBSRELA (tenapanor) for the treatment of irritable bowel syndrome with constipation (IBS-C).
Ardelyx has established agreements with Kyowa Kirin Company Limited in Japan, Fosun Pharma in China and Knight Therapeutics in Canada.

$167 Mn ENT Laser Devices Market - Global Outlook Report 2018-2027 - ResearchAndMarkets.com

Retrieved on:

Friday, September 27, 2019

Medical devices, Health, Companies of China, Companies, Economy of China, Fosun International, Fosun Pharmaceutical, ENT, Laser, Surgical instrument

The "ENT Laser Devices - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "ENT Laser Devices - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's offering.
Some of the most common ENT devices are diagnostic devices, surgical devices and therapeutic devices.
Factors such as the rising number of product launches owing to the growing presence of regional & global vendors and the existence of specialized ENT clinics are contributing to the ENT laser devices market growth in the region.
Some of the key players in global ENT Laser Devices market are Shanghai Fosun Pharmaceutical (Group) Co. Ltd., Boston Scientific Corp., A.R.C.

Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study

Retrieved on:

Monday, September 2, 2019

Companies, Fosun International, Fosun Pharmaceutical, Irritable bowel syndrome, Kirin, Clinical medicine

To participate in the conference call, please dial (855) 296-9612 (domestic) or (920) 663-6277 (international) and refer to conference ID 9789472.

Key Points:

To participate in the conference call, please dial (855) 296-9612 (domestic) or (920) 663-6277 (international) and refer to conference ID 9789472.
Ardelyx is focused on enhancing the lives of people with cardiorenal diseases by developing first-in-class medicines that matter.
To efficiently bring its treatments to market, Ardelyx is pursuing strategic collaborations for tenapanor for IBS-C and hyperphosphatemia in certain territories.
Ardelyx has established agreements with Kyowa Kirin Co., Ltd. in Japan, Fosun Pharma in China and Knight Therapeutics in Canada.

IBSA and Alma Announce Launch of Strategic Partnership at WDC 2019

Retrieved on:

Thursday, June 13, 2019

Stem cells, Surgery, Health, Alternative medicine, Mental health, Other Health, General Health, Medical specialties, Companies of China, Companies, Fosun International, Fosun Pharmaceutical, Rolo, Emilia-Romagna, Reproductive medicine, Urology

The partnership between IBSA and Alma is an interesting response to these new demands, specifically because it combines IBSA's hyaluronic acid-based solutions with Alma's energy-based solutions.

Key Points:

The partnership between IBSA and Alma is an interesting response to these new demands, specifically because it combines IBSA's hyaluronic acid-based solutions with Alma's energy-based solutions.
To validate this new approach, a clinical study will start in September at the University of Modena and Reggio-Emilia."
IBSA operates in 9 main therapeutic areas: Cardiometabolic, Dermatology, Dermoaesthetics, Endocrinology, Reproductive Medicine, Osteoarticular, Pain and Inflammation, Respiratory and Urology.
In 2013, Fosun Pharma, a leading healthcare group in China, acquired Alma through the incorporation of the holding company "Sisram Medical."

Alma Celebrates Its Platinum Anniversary - 20 Years of Global Leadership

Retrieved on:

Tuesday, June 11, 2019

Companies, Fosun International, Fosun Pharmaceutical, Surgery, Draft:Alma Lasers

From its early days, Alma has been at the forefront of medical and aesthetics technologies, carrying the torch of revolution in various arenas around the world, determined to become a market leader.

Key Points:

From its early days, Alma has been at the forefront of medical and aesthetics technologies, carrying the torch of revolution in various arenas around the world, determined to become a market leader.
Today, Alma is a world-leading provider of energy-based solutions for the surgical, medical aesthetics and beauty markets, delivering cutting-edge technologies to its partners and customers in over 80 countries.
Alma is a global innovator of Laser, Light-based, Radiofrequency, Plasma and Ultrasound solutions for the aesthetic and surgical markets.
In April 2013 Alma was acquired by Fosun Pharma, through the establishment of Sisram Medical Ltd., an Israeli holding company, specializing in Medical Technology (Med-Tech).

ReNeuron Partners with Fosun Pharma in China

Retrieved on:

Tuesday, April 9, 2019

Companies of China, Companies, Economy of China, Fosun International, Fosun Pharmaceutical

Fosun Pharma is a leading healthcare group in China with extensive healthcare business interests worldwide.

Key Points:

Fosun Pharma is a leading healthcare group in China with extensive healthcare business interests worldwide.
Under the terms of the Agreement, Fosun Pharma will fully fund the development of ReNeuron's CTX and hRPC cell therapy programmes in China, including clinical development and subsequent commercialisation activities.
Fosun Pharma has also been granted rights to manufacture the licensed products in China.
The collaboration with ReNeuron will contribute to the strategic leading position of Fosun Pharma in this area in China, and also help us to enrich the pipelines for severe disease medical solutions."